Zhang 2017c.

Methods	Study design: Randomised clinical trial Study duration: 2012 to 2014 Duration of follow‐up: 2 years Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by liver biopsy or images; maximal tumour diameter > 5 cm; tumour number ≤ 4; with liver function of Child‐Pugh Class A or B; willing to sign a written informed consent document Exclusion criteria: With history of liver resection or liver transplantation Age (mean ± SD): TACE + MWA: 56.9 ± 7.7 years; TACE alone: 58.2 ± 7.3 years Male (n/total): TACE + MWA: 21/30; TACE alone: 23/30
Interventions	TACE + MWA group (n = 30): TACE: Chemotherapeutic drugs: 5‐fluorouracil 0.075‐1 g and cisplatin 40‐60 mg MWA: The interval between TACE and RFA was 2‐4 weeks. Multiple sessions of MWA were performed, with an interval of 2 weeks. TACE group (n = 30): Chemotherapeutic drugs: 5‐fluorouracil 0.075‐1 g and cisplatin 40‐60 mg
Outcomes	Tumour response, classified as complete response, partial response, stable disease, and progression, measured at 4 weeks after treatment 1‐ and 2‐year survival rates Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.